<DOC>
	<DOCNO>NCT01592331</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , parallel group study evaluate pharmacodynamics pharmacokinetics RO5508887 healthy volunteer . Subjects randomize cohort receive single oral dos either RO5508887 placebo . In-unit period 6 day .</brief_summary>
	<brief_title>A Pharmacodynamic Pharmacokinetic Study RO5508887 Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy male subject , 18 65 year age , inclusive . Healthy status define absence evidence active chronic disease follow detailed medical surgical history complete physical examination Body mass index ( BMI ) 18 30 kg/m2 inclusive Must agree use barrier method contraception treatment period least 30 day last dose study drug Donation blood 500 mL within 6 week drug administration Concomitant disease condition treatment could interfere conduct study would , opinion investigator , pose unacceptable risk subject study Allergy lidocaine Suspicion regular consumption drug abuse Regular smoker ( &gt; 5 cigarette , &gt; 1 pipeful &gt; 1 cigar per day ) Positive hepatitis B , hepatitis C HIV 1 2 infection Participation investigational drug device study ( last administration study drug installation device ) within 6 week RO5508887 administration within 5 mean halflives receive previous investigational drug RO5508887 administration . In addition , subject participate unless completely recover previous invasive study procedure Donation blood 500 mL within 6 week drug administration</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>